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Abstract. The GTP-ase binding domain (GBD) of the signaling protein Wiskott-Aldrich Syndrome Protein 
(WASP) is intrinsically disordered and mutations in it have been linked with Wiskott-Aldrich Syndrome 
(WAS), an X-linked disorder characterized by thrombocytopenia, eczema and recurrent infections. Here, 
we use molecular dynamics simulations and the semi-empirical GROMOS 45A3 force field to study inte-
raction of the GBD domain of WASP with a fragment of the protein EspFU as well as with the VCA do-
main of WASP (auto-inhibited state). EspFU is secreted and used by enterohaemorrhagic Escherichia coli 
to hijack eukaryotic cytoskeletal machinery, and it does so by competitively disrupting the auto-inhibitory 
interaction between GBD and VCA domains of WASP. In addition, naturally occurring mutations in the 
VCA domain cause different variants of WAS. Our simulations confirm that the EspFU domain binds the 
GBD domain similarly to the VCA domain, which explains why these two binding partners are competi-
tive binders of the GBD domain. Furthermore, we propose a possible mechanism to explain the higher af-
finity of EspFU for the GBD domain. Finally, we show that the mutations in the VCA domain responsible 
for Wiskott-Aldrich syndrome can cause formation of β-sheets in the VCA domain. This effect, combined 
with the mutation-induced rearrangement of the salt bridge network, consequently disables tight binding 
between GBD and VCA domains. Overall, our results provide a microscopic, dynamic picture behind the 
two main ways through which the interactions involving the GBD domain of WASP participate in differ-
ent disease processes.(doi: 10.5562/cca1806) 
Keywords: Wiskott-Aldrich syndrome protein, GBD domain, VCA domain, EspFU, molecular dynamics, 
GROMOS 45A3 force field 
 
INTRODUCTION 
Intrinsically disordered proteins (IDPs) or protein frag-
ments are structurally unfolded in their native state. 
These proteins, also known as natively unfolded or 
intrinsically unstructured, are characterized by a lack of 
stable secondary and tertiary structure when unbound in 
solution.1,2 This major characteristic of IDPs has at-
tracted significant attention of the research community 
as it challenges the canonical paradigm of structural 
biology that ordered tertiary structure is the principal 
determinant of protein function. Remarkably, IDPs are 
able to carry out specific functions without well-defined 
secondary or tertiary structure.3,4 What is more, IDPs or 
intrinsically disordered fragments are very common in 
nature. For example, in eukaryotic cells, 30 % of all 
proteins are mostly unfolded, 50 % have long unfolded 
fragments, and 70 % of all signaling proteins are un-
folded under native conditions.5−7 Functionally, IDPs 
are involved in a number of different cellular processes 
including molecular recognition, signal transduction and 
protein modification,1,4,6,7 and have been implicated in 
different diseases such as cancer, diabetes and amyloid 
formation.8,9 Importantly, many IDPs fold into well-
defined structures upon binding to their targets,10 al-
though folding does not always occur.11 Finally, a num-
ber of IDPs have multiple binding partners, suggesting 
that novel physico-chemical mechanisms may be in-
volved, compared with the typically less promiscuous, 
ordered proteins. For example, it has been shown that 
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IDPs can fold into different conformations while bind-
ing to different binding partners.4,12 
The GTP-ase binding domain (GBD domain) of 
the Wiskott-Aldrich Syndrome Protein (WASP) is a 
representative member of the IDP class. According to 
different biophysical characterizations, including circu-
lar dichroism and NMR,13 the GBD domain of WASP is 
largely disordered. WASP is a signaling protein which 
carries signals from membrane receptors to proteins of 
the actin cytoskeleton complex.14 Mutations in the 
WASP gene cause a rare X-linked disorder, Wiskott-
Aldrich Syndrome (WAS), characterized by different 
symptoms depending on the type of mutation in the 
WASP gene. These include thrombocytopenia, eczema 
and recurrent infections caused by immunodeficien-
cy.15,16 The fragments of WASP that are known to be 
unfolded in the native, unbound state are the above-
mentioned GBD domain and the VCA domain (where 
the latter abbreviation stands for Verprolin homology, 
Central hydrophobic and Acidic regions)17 (Figure 1A). 
The GBD domain (residues 230 to 310 of WASP) can 
bind to the GTP-ase Cdc42, but also to the bacterial 
infection protein EspFU.
13,18−21 Furthermore, the GBD 
domain also binds to the VCA domain of the same 
WASP molecule (residues 430 to 502),13 and this 
process leads to auto-inhibition of WASP. Importantly, 
while binding to Cdc42, the GBD domain folds to a 
different structural and functional state as compared to 
the complex with the VCA domain or with EspFU. In 
the latter two complexes, the GBD domain folds in a 
similar way (Figure 1).4,13,17,18 
WASP is inactive when the GBD domain is bound 
to the VCA domain. When the auto-inhibited structure 
is destabilized, the VCA domain of WASP is released 
and can interact with the Arp2/3 actin-nucleating com-
plex, while the GBD domain binds to Cdc42 in the 
activated state.13,18−21 EspFU is a protein that enables 
enterohaemorrhagic E. coli (EHEC) to take control over 
the actin cytoskeleton of the host by bringing under 
control members of the WASP family.18−20 The mechan-
ism of activation of WASP by EspFU is simple and 
direct: it binds to the GBD/VCA binding interface and 
displaces the VCA domain from the GBD domain in a 
competitive fashion.18−20 More specifically, it has been 
shown that a single repeat of the EspFU protein binds 
WASP GBD with a dissociation constant KD = 18 nM,
19 
which is about 100-fold stronger binding than that of 
GBD and VCA.13,19 The release of the auto-inhibitory 
GBD/VCA interaction, in turn, leads to the stimulation 
of the actin nucleation factor, the Arp2/3 complex,21 
which subsequently leads to the formation of actin pe-
destal, an actin-rich protrusion in the membrane under-
 
Figure 1. GBD domain complexes and disorder-prediction profiles of their components. A) GBD domain in complex with the
VCA domain (WASP auto-inhibited form), B) GBD domain in complex with EspFU. In both A and B, we show the original NMR
structures (1st model). C) Disorder prediction by IUPRED, disProt VL3H and DisEMBL for WASP, including GBD and VCA
domains, and D) for the complete EspFU. Segments that were simulated in the present study are indicated on top of the C and D
panels. 
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neath the site where EHEC attach to host cells. In effect, 
the structural mimicry and competitive displacement by 
EspFU of the VCA domain from the GBD domain of 
WASP is the cornerstone underlying EHEC infectivity 
on the molecular level. 
The main goal of the present work is to understand 
the binding behavior of the GBD domain and to find 
differences and similarities between EspFU and the 
VCA domain, which form similar complexes with the 
GBD domain. In particular, we focus on elucidating 
structural and thermodynamic rationales for the greater 
affinity of EspFU for the GBD domain compared with 
the VCA domain.13,18−20 Second, we analyze the muta-
tions in the VCA domain responsible for WAS, and 
elucidate the microscopic background of the destabiliz-
ing effect they have on the GBD/VCA complex. These 
mutations in the VCA domain occur in nature and cause 
the typical form of WAS (K476E)13,22 and the XLT 
form of WAS (R477K).13,23 Overall, our ambition is to 
provide a microscopic, dynamic picture behind these 
two main ways, one mediated by an externally intro-
duced protein and the other one by inherited mutations, 
through which the interactions involving the GBD do-




Molecular dynamics (MD) simulations were performed 
starting from two PDB structures containing the GBD 
domain: 1) GBD domain in complex with VCA domain, 
PDB code 1ej5,13 and 2) GBD domain in complex with 
a fragment of the bacterial protein EspFU, PDB code 
2k42.18 The 1ej5 structure is the auto-inhibited form of 
WASP. It contains the GBD domain (residues 242 to 
310) connected by a short 6-residue linker with the 
cofilin fragment of the VCA domain of WASP (residues 
461 to 492) to which it is bound. The 2k42 structure 
contains the GBD domain (residues 242 to 310) bound 
to a short fragment of the bacterial protein EspFU (resi-
dues 268 to 300, corresponding to residues 1−33 in this 
study), each preceded by a 3-residue linker. Analysis of 
the disordered regions of WASP and EspFU was per-
formed using three different predictors: DisEMBL24 
(loops/coils definition), IUPRED25 (long disorder mode) 
and disProt VL3H.26 The molecular dynamics (MD) 
simulations were performed using Gromacs 3.3 soft-
ware.27 The following systems were simulated: 1) entire 
GBD complexes, i.e. the two structures from the PDB 
database mentioned above; 2) fragments of different 
complexes: GBD domain, VCA domain and the EspFU 
fragment alone, and 3) GBD domain in complex with a 
mutated VCA domain (K476E, R477K). Simulations of 
GBD and VCA domains from 1ej5 in isolation were 
performed with no linker included, while the simula-
tions of GBD and EspFU from 2k42 were performed 
with the preceding 3-residue linkers included in both 
domains. These linkers were excluded in the analysis, 
except for the calculation of solvent accessible surface 
area in the context of solvent entropy estimation, where 
inclusion of linkers was unavoidable. The two mutations 
in the VCA domain were introduced either simulta-
neously or each one separately using PDB2PQR soft-
ware.28,29 
The GROMOS96 45A330 force field and the SPC 
water model31 were used for the simulations. All sys-
tems, except the VCA domain alone, were equilibrated 
using a protocol involving position restraints placed on 
all atoms and then gradually decreasing the strength of 
position restraints, while gradually increasing the tem-
perature in 5 steps. Each of these steps was a 20 ps 
trajectory, simulated in the NVT ensemble. The 5 steps 
were conducted at the following temperatures (in order): 
100, 150, 200, 250, 300 K and with the following re-
spective position restraints (kJ mol−1 nm−2, in all three 
principal directions): 25000, 20000, 15000, 10000, 
5000. This equilibration procedure was carried out with 
a 2 fs time step, reaction field electrostatics, Berendsen 
temperature coupling32 with τcoupling = 0.1 ps, a van der 
Waals cutoff of 1.4 nm and SHAKE33 constraints on all 
bonds. This was followed by 20 ps long equilibration 
simulations in the NPT ensemble at 300 K, with pres-
sure kept at 1 atm using Berendsen pressure coupling32 
with τcoupling = 0.1 ps and κ = 4.5 10
−5 bar−1 and other 
settings unchanged. Production simulations were ex-
tended for 50 ns thereafter for all of the simulated sys-
tems using the same conditions. The VCA domain alone 
was equilibrated using a 2-stage simulated annealing 
procedure. In the first stage, the system was equilibrated 
at 400 K, with the protein position-restrained and the 
water allowed to move freely. In the second stage, the 
system was cooled to 5 K and then heated to 300 K by 
simulated annealing. A single sequence for annealing 
points was used, with two annealing reference/control 
points for each temperature group (protein and solvent) 
at 0 ps and 90 ps. In both stages, we used time-steps of 
2 fs with 50000 steps, reaction field electrostatics and 
Berendsen temperature coupling.32 This was followed 
by a 50 ns production run using the above settings. For 
all of structural analysis, coordinate frames were output 
every 80 ps. A single trajectory was simulated for each 
of the above systems except for the 2k42 structure. 
Namely, to test reproducibility, we also simulated four 
additional trajectories of the 2k42 structure with GBD 
bound to EspFU (for a total of five independent 50 ns 
trajectories), initiated using different velocity assign-
ments. 
Conformational entropy of all proteins in the 
present study was calculated using the quasi-harmonic 
approach employing all-atom, mass-weighted Cartesian 
coordinate covariance matrices.34,35,36 In all cases, trans-
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lational-rotational fitting was performed using all-atoms 
and standard GROMACS routines.27 For entropy analy-
sis, coordinate frames were output every 50 fs. 
 
RESULTS 
The GBD domain of WASP is known experimentally to 
be unfolded when unbound in solution and to fold upon 
binding.13 Moreover, it is known that it folds to similar 
conformations when binding to the VCA domain and 
bacterial protein EspFU
18−20 (Figure 1A and 1B. Overall, 
the backbone RMSD between the two NMR structures 
of the GBD domain is only 0.095 nm (residues 
247−310).18 Most notably, both ligands bind to the GBD 
domain at the same location, interacting with an exten-
sive hydrophobic pocket formed by residues emanating 
from helices α 1−4 of GBD (Figure 1A and 1B). Impor-
tantly, in the original NMR structures the main point of 
contact between GBD and its ligands is through the 
hydrophobic patch. For example, the extensive disor-
dered C-terminal tail of the EspFU domain does not 
directly interact with the GBD domain in the experi-
mental NMR structure, despite the presence of a highly 
hydrophobic tryptophan residue at the fragment’s  
C-terminus. As discussed below, our simulations shed a 
somewhat different light on this. 
The GBD domain is an IDP i.e. it destabilizes (un-
folds) once its binding partners are removed. Its IDP na-
ture is apparent from a bioinformatic analysis of sequence 
disorder propensity, albeit to a lesser extent compared 
with some other regions of WASP (e.g. region 130−230 or 
300−502). We have used three different, widely used 
algorithms for disorder prediction to study its disorder 
properties, with somewhat different results (Figure 1C and 
1D). In particular, the IUPRED predictor,24 which is based 
on estimating the capacity of residues to establish suffi-
cient intramolecular interactions, assigns significant dis-
order probability to the entire GBD sequence (disorder 
probability ≈ 0.6−0.7). On the other hand, the DisEMBL 
predictor,25 which uses a combination of different methods 
to predict disorder including DSSP-based loop assignment 
and crystallographic B-factor information, assigns notice-
ably lower disorder propensity to the GBD domain 
(0.4−0.5). A similar situation is also seen in the case of the 
disProt VL3H predictor,26 a neural network-based algo-
rithm. Overall, it is possible that this borderline disorder 
propensity of the GBD domain is related to the fact that 
this domain folds upon binding i.e. can exist in both 
folded and unfolded state depending on its molecular 
environment. Finally, both partners of the GBD domain, 
VCA and EspFU, appear significantly intrinsically disor-
dered when studied using IUPRED and DisEMBL algo-
rithms (Figure 1C and 1D), while disProt VL3H produces 
a more checkered profile, albeit with significant stretches 
corresponding to complete disorder. 
What are the main structural features of the GBD 
domain in the unbound form? To address this question, 
we have simulated two structures of the isolated GBD, 
one taken from the complex with the VCA domain and 
the second from the complex with EspFU. The GBD 
domains alone were simulated starting from their li-
 
Figure 2. Backbone atom-positional RMSD from starting
structures for different simulated systems. A) GBD/VCA
complex: GBD domain simulated alone (red), GBD domain
when in complex with VCA domain (blue), VCA domain
alone (green); B) GBD/EspFU: GBD domain simulated alone
(green), GBD domain alone simulated in complex with EspFU
(red) and EspFU domain alone (blue); C) GBD from a com-
plex with K476E mutation (purple), GBD from a complex
with R477K mutation (orange), GBD from a complex with
both K476E and R477K mutations (green), VCA with K476E
mutation (dark blue), VCA with R477K mutation (red), VCA
with both K476E and R477K mutations (light blue). All simu-
lations and calculations in C) were performed in the context of
the GBD/VCA complex. 
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gand-bound conformations, after removing the binding 
partners. Analysis of the simulated trajectories shows 
that the GBD domains in the unbound form largely lose 
their secondary and tertiary structure, and the degree of 
change in the two folded GBD domains alone is similar: 
the average RMSD over the last 30 ns of the trajectory 
is approximately 1 nm for both GBD folded structures 
(Figure 2) (RMSD of GBD from complex with VCA = 
1.08 ± 0.01 nm, RMSD of GBD from complex with 
EspFU.= 0.93 ± 0.02 nm). Furthermore, during simula-
tion of the isolated GBD domain, the molecule lost a 
large fraction of its α-helical secondary structure con-
tent. Namely, it changed from 42.7 ± 2.8 % and 41.4 ± 
2.6 % of all residues in the bound form to 24.8 ± 3.3 % 
and 20.1 ± 2.4 % in the unbound form, for VCA and 
EspFU complexes, respectively. These results confirm 
that the GBD domain without a binding partner is sig-
nificantly destabilized, which is in agreement with prior 
biophysical studies13 and the results of sequence-based 
predictions discussed above. Notably, in both cases, 
structural destabilization of the GBD domain upon li-
gand removal occurs without any major change in the 
molecule’s radius of gyration, Rg (1.18 ± 0.02 nm versus 
1.18 ± 0.02 nm for GBD from VCA and EspFU com-
plexes, respectively) or solvent-accessible surface area, 
SASA (50.12 ± 1.69 nm2, 49.97 ± 1.69 nm2 for GBD 
from VCA and EspFU complexes, respectively). These 
values should be compared with the values from expe-
rimental structures of 1.14 nm (Rg of GBD from VCA 
complex), 1.17 nm (Rg of GBD from EspFU complex), 
and 51.11 nm2 (SASA of GBD from VCA complex) and 
50.59 nm2 (SASA of GBD from EspFU complex). In 
other words, although it loses a significant part of its 
secondary and tertiary structure, GBD domain in isola-
tion retains its overall compactness. 
In contrast, the GBD domain in complex with its 
binding partners is significantly more stable than when 
alone. For example, the GBD domain in complex with 
VCA exhibits an average backbone RMSD from the 
starting structure of 0.47 ± 0.03 nm over the last 30 ns 
in the two trajectories combined together (Figure 2A). 
The same trend is seen during the simulation of the 
GBD-EspFU complex (<RMSD>
20−50 ns = 0.4 ± 0.02 nm, 
compared with the starting structure) (Figure 2B). Inte-
restingly, when the two WAS-inducing mutations are 
introduced into the GBD+VCA structure simultaneous-
ly, the whole complex destabilizes in several tens of 
nanoseconds, as shown by the RMSD of mutated com-
plexes which is almost twice as big as the RMSD of the 
complex without mutation (e.g. RMSD of GBD + VCA 
for the double mutant is 1.46 ± 0.02 nm, RMSD of GBD 
+ VCA is 0.79 ± 0.03 nm, for the double mutant both 
with respect to the starting structure). Importantly, when 
it comes to both secondary and tertiary structure, these 
two mutations result in a similar level of structural dis-
integration of the GBD domain as when its ligands are 
removed (Figure 2C). However, when they are intro-
duced individually, the GBD domain retains its struc-
tural stability throughout the simulated trajectories 
(Figure 2C). 
Our simulations also allowed us to address a me-
thodological question. Namely, as discussed above, 
there are a number of different sequence-based algo-
rithms for predicting protein disorder. On the other 
hand, MD simulations give a direct view of protein 
disorder. How do the two approaches compare? We 
have carried out an analysis of the degree of disorder in 
the simulated unbound and bound states of GBD, VCA 
and EspFU to compare them with the results of se-
quence-based prediction algorithms (Figures 1 and S1, 
see Supplementary Materials for methodological de-
tails). Interestingly, there is significant qualitative 
agreement about the general degree of disorder on a 
site-resolved basis, especially in comparison with Dis-
EMBL predictions, and to a lesser extent with IUPRED 
predictions (Figures 1 and S1). On the other hand, the 
results of the disPROT VL3H predictor deviate signifi-
cantly from the MD results. In some ways, the differ-
ence between MD-predicted disorder and sequence-
based predictions is of a similar order as that between 
predictions using different sequence-based algorithms 
themselves (Figure 1). 
What is the mode of binding of EspFU to the GBD 
domain? According to Cheng et al.,18 this protein binds 
to the GBD domain in a similar way to the VCA do-
main. Moreover, these researchers also found that resi-
dues 16 to 20 of EspFU form additional interactions with 
the GBD domain (as compared to the VCA domain), 
whereas residues 21 to 33 are reported to be largely 
unfolded and not interacting with the GBD domain 
(Figure 3A). Contrary to this, our simulations show that 
residues 21 to 33 of EspFU interact directly with the 
GBD domain (Figure 3B, C and 4). In particular, the tail 
region of EspFU appears to adopt a dynamic, U-shaped, 
extended conformation, encompassing almost half of 
the GBD domain. This structure is stabilized by a direct 
interaction between W33 in EspFU and different resi-
dues located on the diametrically opposite side of the 
GBD domain compared to the helix-binding site (Fig-
ures 3 and 4). Out of five independent simulations of 
this complex, four have resulted in EspFU’s W33 being 
bound to GBD, with only one simulation resulting in an 
unbound W33 after 50 ns. For example, in one of the 
simulations W33 binds to the highly hydrophobic pock-
et formed by residues V254, L267 and L300 in GBD 
(Figure 3B and C). A similar, hydrophobic interaction 
between W33 and GBD’s V264 is seen in another simu-
lation, while in the remaining two the interactions are 
more of an electrostatic nature (e.g. with H253 and 
R308, Figure 4A). These additional interactions provide 
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a potential explanation for EspFU’s higher binding affin-
ity, as discussed below. In terms of kinetics, the interac-
tions between W33 in EspFU and different binding sites 
on GBD are typically established after approximately  
10 ns and remain present for the rest of the trajectories 
(Figure 4B). We have also analyzed other potential 
interactions between the tail region of EspFU and GBD, 
but there were no other major conspicuous interactions 
seen. For example, potential salt-bridge-forming resi-
dues R21 and E25 in EspFU remain exposed to the sol-
vent and do not form any interactions with the GBD 
domain. 
Despite their relatively stable structure compared 
to that of either GBD or VCA or EspFU alone, the com-
plexes of GBD with the two ligands are still dynamic, as 
indicated by the relatively sizable RMSD from the start-
ing structures (Figure 2). This suggests that conforma-
tional entropy may be a relevant factor determining the 
relative affinities of VCA and EspFU for the GBD do-
main. We have evaluated conformational entropy dif-
ferences between EspFU and VCA complexes with the 
GBD domain, and the results are intriguing (Figure 4). 
First, the conformational entropy contribution to the free 
energy (−TΔSQH) of just the GBD domain in complex 
with EspFU is approximately 250 kJ/mol more positive 
than that of GBD in complex with VCA for the period 
of 20−50 ns in our simulations, as evaluated by the 
quasi-harmonic approach at T = 300 K (Figure 5, GBD). 
Similarly, the conformational entropy part of free ener-
gy of just the VCA domain in complex with GBD is 
 
Figure 3. Binding of EspFU to GBD. Structures of the GBD/EspFU complexes from: A) NMR experiment (bundle of 20 lowest
energy structures), B) MD simulation (bundle of 20 structures between 20 and 50 ns, spaced every 1.5 ns). C) close-up of the
hydrophobic binding pocket for W33 seen in our simulations. Hydrophobic residues are colored white, while all other are green. 
 
Figure 4. EspFU binds to different binding locations on GBD. A) locations of all of the detected binding locations on GBD for
EspFU’s C-terminal W33 residue. B) time course of binding of W33 to different locations on GBD. 
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approximately 100 kJ/mol more favorable than that of 
the EspFU fragment over the same stretch (Figure 5, 
ligands bound). Interestingly, the difference is very 
similar for the unbound ligands as well (ligands free). 
On the other hand, if one analyzes complete complex-
es, it appears that the conformational entropy part of 
the free energy change is about 1500 kJ/mol more 
favorable for the GBD/EspFU than for the GBD/VCA 
complex at 300 K (Figure 5, complex). Curiously, this 
is only so if one treats the entire complex as one unit 
when it comes to rotation/translation fitting in the 
course of quasi-harmonic analysis. If, on the other 
hand, one calculates the conformational entropy of 
each complex as a sum of individual contributions 
coming from GBD and the ligand in question, one sees 
the opposite behavior: in that case, the VCA complex 
becomes more favorable by approximately 300 kJ/mol 
(Figure 5, complex*). These results, taken together, 
suggest that the relative movement of the GBD domain 
and EspFU in the bound state, rather than their intrinsic 
dynamics, may be responsible for increasing the con-
formational entropy content of this complex. Finally, 
we have also evaluated the solvent entropy contribu-
tion to the binding free energy change for the two 
complexes. Assuming that the solvent entropy change 
is proportional to the change in solvent accessible 
surface area of the two complexes and their constitut-
ing fragments upon binding, and using the formalism 
of Freire et al.,37,38 our simulations suggest that the 
solvent entropy contribution to the binding free energy 
change is about 28.4 kJ/mol more favorable at T = 300 
K for the GBD/EspFU as compared to the GBD/VCA 
complex, which is significantly less in absolute magni-
tude than conformational entropy. 
Binding of EspFU is an example of how modula-
tion of GBD and VCA interactions can lead to a disease 
process and, in this case, modulation is caused by an 
externally introduced factor. However, inherited muta-
tions can also affect these interactions and directly lead 
to abnormal physiological activity. As discussed above, 
mutations in the VCA domain (K476E and R477K) are 
known to cause different forms of WAS.13,22,23 These 
mutations occur at the C-terminus of the VCA domain,18 
and we have introduced them in our simulations either 
simultaneously or one at a time. As a consequence of 
introducing the mutations simultaneously, the whole 
complex significantly destabilizes (Figure 2C). The 
RMSD for the entire structure reaches 1 nm (Figure 
2A), even though RMSD for individual α-helical frag-
ments in the GBD domain is small (<0.2 nm in all cas-
es). After introducing the mutations, we also observe 
formation of a β-sheet in the VCA domain in the course 
of the simulation trajectory. Secondary structure time-
series DSSP plots demonstrate the appearance of this 
additional secondary structure already within the first 
few nanoseconds of simulation (Figure 6). Importantly, 
GBD domain’s helices maintain their structure, as indi-
cated by a sizable fraction of α-helical residues over the 
last 30 ns of the trajectory (33.8 ± 1.9 %) but do start to 
move away from each other. 
Finally, and this we believe is the main cause of 
structural disintegration, the doubly mutated 
GBD+VCA complex also exhibits a major rearrange-
ment of the salt-bridge network keeping the complex 
together. Namely, in the native state, there is a strong 
interaction of K476 and R477 with the 292−296 seg-
ment of the GBD domain (K476 with D292 and D296, 
and R477 with D292 only) (Figure 7A and 7B). Moreo-
Figure 5. Analysis of the contribution of quasi-harmonic conformational entropy to free energy of GBD complexes. In all of the
graphs in A), we plot cumulative values of −TΔSQH, as a function of total time and normalized by the number of atoms, for the
difference between EspFU and VCA-bound complexes, including the difference for the ligands (both bound and free), GBD do-
mains, as well as for complete complexes, calculated either by performing quasi-harmonic conformational entropy analysis on
individual components of the complex, and then adding the contributions up (complex*), or on the whole complex (complex). B)
close-up of A). 
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ver, R477 also interacts with E285 and K288 (Figure 
7C). The interactions with D292 and E28513 have been 
reported to be very important for the GBD/VCA bind-
ing. The mutation K476E changes the positively 
charged residue into a negatively charged one and, ex-
pectedly, results in the loss of salt bridges at position 
476 with the GBD domain. Consequently, what we 
observe is a shift of salt-bridge-forming „responsibility” 
in this region of the structure from the native 
K476/R477 pair to the mutated K477, joined by R479 
whose salt-bridging network also significantly changes 
upon mutations of K476 and R477 (not shown). Most 
notably, R479, which before mutations formed salt 
bridges inside the VCA domain only, now interacts with 
two different GBD residues (D292 and E295). In addi-
tion, it also takes over the salt bridge with E476 (which 
interacted with R477 before the mutation). However, its 
interactions with D485 and E488 are now lost. Strong 
salt-bridge interactions are preserved with the 
D292−D296 segment of GBD (with an additional salt 
bridge forming with E295 and with the salt bridge to 
D296 appearing to be more stable and stronger) (Figure 
7). However, salt bridges with E285 and K288 of the 
GBD domain appear to be lost. Moreover, K477 now 
fails to form salt bridges with E486 and D489 that R477 
interacted with before the mutation. In short, the double 
mutation preserves strong interactions of VCA with the 
292−296 segment of GBD, results in the loss of interac-
tion with 285−288 of GBD and most importantly, leads 
to a loss of salt bridges to D485, E486, E488 and D489 
which we propose is responsible for the destabilization 
of the VCA domain. Finally, we postulate that the ab-
rupt loss of salt bridge interactions within the 485−489 
fragment favors the formation of a β-sheet, as discussed 
above, further destabilizing the native conformation of 
the VCA domain. Interestingly, individual mutations in 
the VCA domain do not lead to any major reorganiza-
tion or unfolding of the GBD domain, but they do in-
duce unfolding of the VCA domain similar to the one 
discussed here (Figure 2C). Finally, structural rear-
rangement of the GBD/VCA complex in the presence of 
mutations also leads to a change in its dynamic beha-
vior. As the most important consequence, the conforma-
tional entropy of the complex decreases in all three 
cases, indicative of a reduction in the molecule’s flex-
ibility. More precisely, relative to the conformational 
entropy of the native complex (26.7 kJ mol−1 K−1), the 
conformational entropy of the K476E mutant is 1.1 kJ 
mol−1 K−1 lower, that of the R477K mutant 1.7 kJ mol−1 
K−1 lower, and that of the double mutant 1.3 kJ mol−1 
K−1 lower. Using the conformational entropy, solvent 
entropy and enthalpy contributions, one can also esti-
mate the free energy change of binding upon mutation. 
While the quantitative details are likely imprecise, using 
this approach, and assuming that the solvent-protein 
enthalpic contribution does not change, we obtain that 
the effect of each of the three mutations is, as expected, 
unfavorable compared to the wild type (ΔΔGmut = 562.9 
kJ/mol, 247.4 kJ/mol and 375.3 kJ/mol for K476E, 
R477K and the double mutant, respectively). 
 
DISCUSSION 
MD simulations are a powerful method for investigating 
the behavior of biomolecular systems on the atomistic 
level and with femtosecond temporal resolution39. Using 
different 50 ns MD simulations, we have shown that the 
EspFU fragment binds the GBD domain with additional 
Figure 6. Secondary structure analysis of GBD/VCA com-
plexes. A) GBD domain in complex with the VCA domain,
and B) GBD domain in complex with the mutated VCA do-
main. The formation of an additional β-sheet at the N-terminus 
of the VCA domain occurs in the mutated complex. 
Figure 7. Salt-bridge analysis of GBD/VCA complexes. 
Time-course of salt-bridge pairings: of A) native K476, B) 
native R477, C) mutated E476 and D) mutated K477. 
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interactions of its C-terminal tail, which wraps around 
the GBD domain and could contribute to EspFU’s higher 
binding affinity as a competitive binder to the VCA 
domain. Second, our simulations allowed us to dissect 
the contribution of conformational entropy to the differ-
ence between VCA and EspFU in binding to the GBD 
domain. Finally, our simulations have shown that the 
molecular basis of the destabilization of the GBD do-
main complex with the VCA domain consists primarily 
of the destabilization of salt bridges within the VCA 
domain. 
Cheng et al.18 have experimentally shown that the 
first 18 residues of the EspFU fragment bind to the GBD 
domain with a KD of 4 ± 2 μM, while if the additional 
15 residues of the C-terminal tail are included, the affin-
ity rises to a KD of 35 ± 4.9 nM. We would like to sug-
gest that this additional stabilization of the complex is 
due to the strong interaction of W33 with different hy-
drophobic pockets on GBD, as discussed above, or other 
binding interactions of this residue with the GBD sur-
face. The interaction of W33 with GBD was not de-
tected by NMR,18 but given the heterogeneity of its 
potential binding sites on GBD, as seen in our simula-
tions, this is to be expected. Importantly, we did not 
detect any other major interactions (e.g. salt bridges) 
between the C-terminal tail of EspFU and the rest of 
GBD, suggesting that the above-mentioned hydrophobic 
and/or electrostatic interactions may be the key deter-
minant of binding affinity. Further experimental work 
should shed more light on this possibility: in particular, 
our simulations predict that mutating W33 to a more 
hydrophilic amino acid would have a major effect in the 
direction of reducing the binding affinity of EspFU. 
Similarly, we predict that structure-preserving mutations 
in the hydrophobic pockets on the GBD domain sur-
rounding V254 and V264, whereby these pockets would 
be rendered more hydrophilic, would produce a similar 
effect. 
Using quasi-harmonic approaches, we have calcu-
lated the conformational entropy of GBD and its com-
plexes. Most importantly, we have found that when it 
comes to conformational entropy, binding of EspFU is 
more favorable compared to VCA, under the assump-
tion that their conformational entropies in the unbound 
state are similar. Although our simulations were poten-
tially not long enough to reach fully converged confor-
mational entropy values, most notably in the case of 
disordered conformers, it is possible that the trends seen 
in our simulations would remain valid even with more 
extensive sampling. Additionally, quasi-harmonic anal-
ysis critically depends on precise roto-translational 
fitting of structures, and it is possible that in the case of 
more mobile complexes, such as GBD/EspFU, this may 
be difficult to optimally perform. Limited sampling and 
fitting artifacts notwithstanding, this analysis suggests 
that a part of the rationale for higher affinity of EspFU 
for GBD, and for its competitive displacement of the 
VCA domain, may reside in conformational entropy 
contributions. However, there are likely other rationales 
for this, both entropic and enthalpic in nature. For ex-
ample, we would like to suggest that the fact that EspFU 
is actually expressed as a sequence of 5−6 highly simi-
lar repeats19 (Figure 1D) increases to a major degree the 
affinity of EspFU for GBD. By concatenating 5−6 EspFU 
binding motifs, the overall affinity of the complete Esp-
FU for its target is multiplicatively increased. Sallee et 
al.19 have demonstrated that multiple repeats of EspFU 
are needed for powerful activation of actin polymeriza-
tion, and have suggested that this is due to EspFU bind-
ing multiple WASP proteins. Of course, this mechanism 
is largely independent of our suggestion that multiple 
repeats increase affinity – it is possible that both me-
chanisms operate in parallel. Finally, it is also possible 
that the favorable conformational entropy of the EspFU 
complex may be counteracted by an opposite trend 
when it comes to EspFU or VCA alone in solution. 
By analyzing and comparing in parallel two dif-
ferent molecular scenarios which lead to disease in the 
context of WASP, we hope to have provided a founda-
tion which could contribute to finding new pharmaco-
logical treatments for Wiskott-Aldrich Syndrome. In 
addition, we hope the findings presented herein will 
help harness the tremendous potential of IDP molecules 
like GBD, EspFU or VCA to be used in different con-
texts ranging from enzyme design and nanotechnology 
to biotechnology. 
Supplementary Materials. – Supporting information to the 
paper is enclosed to the electronic version of the article. This 
data can be found on the website of Croatica Chemica Acta 
(http://public.carnet.hr/ccacaa). 
Acknowledgements. We thank the members of the Laboratory 
of Computational Biophysics at MFPL for useful comments 
on the manuscript. In particular, we would like to thank Pawel 
Janowski for careful reading of the manuscript and editing 
suggestions. This work was supported in part by the National 
Foundation for Science, Higher Education and Technological 
Development of Croatia (EMBO Installation grant to BZ), the 
Unity Through Knowledge Fund of Croatia (UKF 1A grant to 
BZ) and the Austrian Science Fund FWF (START Award Y 
514-B11 to BZ). 
 
REFERENCES 
1. A. F. Fink, Curr. Opin. Struc. Biol. 15 (2005) 35−41. 
2. P. Radivojac, L. M. Iakoucheva, C. J. Oldfield, Z. Obradovic, 
and V. N. Uversky, Biophys. J. 92 (2007) 1439−1456. 
3. A. Schlessinger, M. Punta, and B. Rost, BMC Bioinformatics. 23 
(2007) 2376−2384. 
4. H. J. Dyson and P. E. Wright, Curr. Opin. Struct. Biol. 12 (2002) 
54−60. 
220 M. K. Janowska et al., Binding of the GBD Domain of WASP 
Croat. Chem. Acta 84 (2011) 211. 
5. J. J. Ward, S. J. Sodhi, L. J. McGuffin, B. F. Buxton, and D. T. 
Jones, J. Mol. Biol. 337 (2004) 635−645. 
6. L. M. Iakoucheva, C. J. Brown, J. D. Lawson, Z. Obradovic, and 
A. K. Dunker, J. Mol. Biol. 323 (2002) 573−584. 
7. A. K. Dunker, C. J. Brown, J. D. Lawson, L. M. Iakoucheva, and 
Z. Obradovic, Biochemistry-US 41 (2002) 6574−6582. 
8. V. N. Uversky, C. J. Oldfield, and A. K. Dunker, Ann. Rev. Bio-
phys. 37 (2008) 215−246. 
9. V. N. Uversky, C. J. Oldfield, U. Midic, H. Xie, B. Xue, S. Vu-
cetic, L. M. Iakoucheva, Z. Obradovic, and A. K. Dunker, BCM 
Genomics 10(Suppl I) (2009) S7. 
10. V. N. Uversky, Protein Sci. 11 (2002) 739−756. 
11. A. B. Sigalov, A. V. Zhuravleva, and V. Y. Orekhov, Biochimie 
89 (2007) 419−421. 
12. L. M. Espinoza-Fonseca, Biochem. Bioph. Res. Co. 382 (2009) 
479−482. 
13. A. S. Kim, L. T. Kakalis, N. Abdul-Manan, G. A. Liu, and M. K. 
Rosen, Nature 404 (2000) 151−158. 
14. A. J. Thrasher and S. O. Burns, Nat. Rev. Immunol. 10 (2010) 
182−192. 
15. H. D. Ochs and A. J. Thrasher, J. Allergy Clin. Immunol. 117 
(2006) 725−738. 
16. L. D. Nortarangelo, C. H. Miao, and H. D. Ochs, Curr. Opin. 
Hematol. 15(1) (2008) 30−36. 
17. N. Abdul-Manan, B. Aghazadeh, A. G. Liu, A. Majumdar, O. 
Ouerfelli, S. A. Siminovitch, and M. S. Rosen. Nature 399 
(1999) 379−383. 
18. H. Cheng, B. M. Skehan, K. G. Campellone, J. M. Leong, and 
M. K. Rosen, Nature 454 (2008) 1009−1014. 
19. N. A. Sallee, G. M. Rivera J. E. Dueber, D. Vasilescu, R. Dyche 
Mullins, B. J. Mayer, and W. A. Lim, Nature 454 (2008) 
1005−1008. 
20. S. B. Padrick and M. K. Rosen, Annu. Rev. Biochem. 79 (2010) 
707−735. 
21. H. N. Higgs and T. D. Pollard, Annu. Rev. Biochem. 70 (2001) 
649−676. 
22. R. Kolluri, A. Chehabeldin, M. Peacocke, A-M. Lamhonwah, K. 
Teichert-Kuliszewska, S. M. Weissman, and K. A. Simonovitch, 
Hum. Mol. Genet. 4 (1995) 1119−1126. 
23. J. M. J. Derry, J. A. Kerns, K. I. Weinberg, H. D. Ochs, V. Vol-
pini, X. Estivill, A. P. Walker, and U. Francke, Hum. Mol. Genet. 
4 (1995) 1127−1135. 
24. Z. Dosztanyi, V. Csizmok, P. Tompa, and I. Simon, Bioinformat-
ics. 21 (2005) 3433−3434. 
25. R. Linding, L. J Jensen, F. Diella, P. Bork, T. J. Gibson, and R. 
B. Russell, Structure 11 (2003) 1453−1459. 
26. Z. Obradovic, K. Peng, S. Vucetic, P. Radivojac, C. J. Brown, 
and A. K. Dunker, Prot. Struc. Funct. Genet. 53 (2003) 
566−572. 
27. D. van der Spoel, E. Lindahl, B. Hess, A. R. van Buuren, E. 
Apol, P. J. Meulenhoff, D. P. Tieleman, A. L. T. M. Sijbers, K. 
A. Feenstra, R. van Drunen, and H. J. C. Berendsen, Gromacs 
User Manual version 3.3 2005. 
28. T. J. Dolinsky, P. Czodrowski, H. Li, J. E. Nielsen, J. H. Jensen, 
G. Klebe, and N. A. Baker NA, Nucleic Acids Res. 35 (2007) 
W522-5. 
29. T. J. Dolinsky, J. E. Nielsen, J. A. McCammon, and N. A. Baker, 
Nucleic Acids Res. 32 (2004) W665−W667. 
30. L. D. Schuler, X. Daura, and W. F. van Gunsteren, J. Comput. 
Chem. 22 (2001) 1205−1218. 
31. H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren, and J. 
Hermans, Intermolecular Forces Pullman B. (ed.). Reidel, Dor-
drecht, 1981, p. 331. 
32. H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren, A. 
DiNola, and J.R. Haak, J. Chem. Phys. 81 (1984) 3684–3690. 
33. J-P. Ryckaert, G. Ciccotti, and H. J. C. Berendsen. J. Comput. 
Phys. 23 (1977) 327–341. 
34. M. Karplus and J. N. Kushick, Macromolecules 14 (1981) 
325−332. 
35. R. M. Levy, M. Karplus, J. Kushick, and D. Perahia, Macromo-
lecules 17 (1984) 1370−1374. 
36. I. Andricioaei and M. Karplus. J. Chem. Phys. 115 (2001) 
6289−6292. 
37. J. A. D’Aquino, J. Gomez, V. J. Hilser, K. H. Lee, L. M. Amzel, 
and E. Freire. Prot. Struc. Funct. Genet. 25 (1996) 143−156. 
38. V. J. Hilser, B. E. Garcia-Moreno, T. G. Oas, G. Kap, and S. T. 
Whitten. Chem. Rev. 106 (2006) 1545−1558. 
39. W. F. van Gunsteren , D. Bakowies, R. Baron, I. Chandrasekhar, 
M. Christen, X. Daura, P. Gee, D. P. Geerke, A. Glattli, P. H. 
Hunenberger, M. A. Kastenholz, C. Oostenbrink, M. Schenk, D. 
Trzesniak, N. F. A. van der Vegt, and H. B. Yu, Angew. Chem. – 
Inter. Ed. 45 (2006) 4064−4092. 
 
